Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for the adjuvant treatment of resected stage 2 melanoma with high risk of recurrence
Status In progress
Process STA 2018
ID number 3908

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
08 September 2021 - 06 October 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
23 March 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance